Literature DB >> 30108971

Reduction-rebridging strategy for the preparation of ADPN-based antibody-drug conjugates.

Oleksandr Koniev1, Igor Dovgan2, Brigitte Renoux3, Anthony Ehkirch4,5, Jitka Eberova2, Sarah Cianférani4,5, Sergii Kolodych1, Sébastien Papot3, Alain Wagner2.   

Abstract

The reduction-rebridging strategy is a powerful method for the preparation of stable and homogeneous antibody-drug conjugates (ADCs). In this communication, we describe the development of the arylene-dipropiolonitrile (ADPN) functional group for the rebridging of reduced disulphide bonds and its application in the preparation of potent and selective ADCs.

Entities:  

Year:  2018        PMID： 30108971      PMCID： PMC6071946          DOI： 10.1039/c8md00141c

Source DB:  PubMed          Journal:  Medchemcomm        ISSN： 2040-2503            Impact factor:   3.597


  19 in total

1.  Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates.

Authors:  Pavel Strop; Shu-Hui Liu; Magdalena Dorywalska; Kathy Delaria; Russell G Dushin; Thomas-Toan Tran; Wei-Hsien Ho; Santiago Farias; Meritxell Galindo Casas; Yasmina Abdiche; Dahui Zhou; Ramalakshmi Chandrasekaran; Caroline Samain; Carole Loo; Andrea Rossi; Mathias Rickert; Stellanie Krimm; Teresa Wong; Sherman Michael Chin; Jessica Yu; Jeanette Dilley; Javier Chaparro-Riggers; Gary F Filzen; Christopher J O'Donnell; Fang Wang; Jeremy S Myers; Jaume Pons; David L Shelton; Arvind Rajpal
Journal:  Chem Biol       Date:  2013-02-21

2.  Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering.

Authors:  Thomas H Pillow; Janet Tien; Kathryn L Parsons-Reponte; Sunil Bhakta; Hao Li; Leanna R Staben; Guangmin Li; Josefa Chuh; Aimee Fourie-O'Donohue; Martine Darwish; Victor Yip; Luna Liu; Douglas D Leipold; Dian Su; Elmer Wu; Susan D Spencer; Ben-Quan Shen; Keyang Xu; Katherine R Kozak; Helga Raab; Richard Vandlen; Gail D Lewis Phillips; Richard H Scheller; Paul Polakis; Mark X Sliwkowski; John A Flygare; Jagath R Junutula
Journal:  J Med Chem       Date:  2014-09-18       Impact factor: 7.446

3.  Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.

Authors:  Christopher R Behrens; Edward H Ha; Lawrence L Chinn; Simeon Bowers; Gary Probst; Maureen Fitch-Bruhns; Jorge Monteon; Amanda Valdiosera; Abel Bermudez; Sindy Liao-Chan; Tiffany Wong; Jonathan Melnick; Jan-Willem Theunissen; Mark R Flory; Derrick Houser; Kristy Venstrom; Zoia Levashova; Paul Sauer; Thi-Sau Migone; Edward H van der Horst; Randall L Halcomb; David Y Jackson
Journal:  Mol Pharm       Date:  2015-10-02       Impact factor: 4.939

4.  Bridging disulfides for stable and defined antibody drug conjugates.

Authors:  George Badescu; Penny Bryant; Matthew Bird; Korinna Henseleit; Julia Swierkosz; Vimal Parekh; Rita Tommasi; Estera Pawlisz; Kosma Jurlewicz; Monika Farys; Nicolas Camper; XiaoBo Sheng; Martin Fisher; Ruslan Grygorash; Andrew Kyle; Amrita Abhilash; Mark Frigerio; Jeff Edwards; Antony Godwin
Journal:  Bioconjug Chem       Date:  2014-05-23       Impact factor: 4.774

5.  CBTF: new amine-to-thiol coupling reagent for preparation of antibody conjugates with increased plasma stability.

Authors:  Sergii Kolodych; Oleksandr Koniev; Zoljargal Baatarkhuu; Jean-Yves Bonnefoy; François Debaene; Sarah Cianférani; Alain Van Dorsselaer; Alain Wagner
Journal:  Bioconjug Chem       Date:  2015-01-23       Impact factor: 4.774

6.  MAPN: First-in-Class Reagent for Kinetically Resolved Thiol-to-Thiol Conjugation.

Authors:  Oleksandr Koniev; Sergii Kolodych; Zoljargal Baatarkhuu; Johann Stojko; Jitka Eberova; Jean-Yves Bonnefoy; Sarah Cianférani; Alain Van Dorsselaer; Alain Wagner
Journal:  Bioconjug Chem       Date:  2015-09-03       Impact factor: 4.774

7.  Development of Novel Quaternary Ammonium Linkers for Antibody-Drug Conjugates.

Authors:  Patrick J Burke; Joseph Z Hamilton; Thomas A Pires; Jocelyn R Setter; Joshua H Hunter; Julia H Cochran; Andrew B Waight; Kristine A Gordon; Brian E Toki; Kim K Emmerton; Weiping Zeng; Ivan J Stone; Peter D Senter; Robert P Lyon; Scott C Jeffrey
Journal:  Mol Cancer Ther       Date:  2016-03-04       Impact factor: 6.261

8.  Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates.

Authors:  Robert P Lyon; Jocelyn R Setter; Tim D Bovee; Svetlana O Doronina; Joshua H Hunter; Martha E Anderson; Cindy L Balasubramanian; Steven M Duniho; Chris I Leiske; Fu Li; Peter D Senter
Journal:  Nat Biotechnol       Date:  2014-09-07       Impact factor: 54.908

9.  Functional native disulfide bridging enables delivery of a potent, stable and targeted antibody-drug conjugate (ADC).

Authors:  João P M Nunes; Maurício Morais; Vessela Vassileva; Eifion Robinson; Vineeth S Rajkumar; Mark E B Smith; R Barbara Pedley; Stephen Caddick; James R Baker; Vijay Chudasama
Journal:  Chem Commun (Camb)       Date:  2015-06-05       Impact factor: 6.222

10.  A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy.

Authors:  Antoine Maruani; Mark E B Smith; Enrique Miranda; Kerry A Chester; Vijay Chudasama; Stephen Caddick
Journal:  Nat Commun       Date:  2015-03-31       Impact factor: 14.919
View more
  4 in total

1.  All-in-one disulfide bridging enables the generation of antibody conjugates with modular cargo loading.

Authors:  Friederike M Dannheim; Stephen J Walsh; Carolina T Orozco; Anders Højgaard Hansen; Jonathan D Bargh; Sophie E Jackson; Nicholas J Bond; Jeremy S Parker; Jason S Carroll; David R Spring
Journal:  Chem Sci       Date:  2022-07-20       Impact factor: 9.969

2.  Plasmonic photothermal release of docetaxel by gold nanoparticles incorporated onto halloysite nanotubes with conjugated 2D8-E3 antibodies for selective cancer therapy.

Authors:  Reza Taheri-Ledari; Wenjie Zhang; Maral Radmanesh; Nicole Cathcart; Ali Maleki; Vladimir Kitaev
Journal:  J Nanobiotechnology       Date:  2021-08-11       Impact factor: 10.435

3.  An overview of chemo- and site-selectivity aspects in the chemical conjugation of proteins.

Authors:  Charlotte Sornay; Valentine Vaur; Alain Wagner; Guilhem Chaubet
Journal:  R Soc Open Sci       Date:  2022-01-26       Impact factor: 2.963

4.  Divinylpyrimidine reagents generate antibody-drug conjugates with excellent in vivo efficacy and tolerability.

Authors:  Stephen J Walsh; Soleilmane Omarjee; Friederike M Dannheim; Dominique-Laurent Couturier; Dorentina Bexheti; Lee Mendil; Gemma Cronshaw; Toby Fewster; Charlotte Gregg; Cara Brodie; Jodi L Miller; Richard Houghton; Jason S Carroll; David R Spring
Journal:  Chem Commun (Camb)       Date:  2022-02-08       Impact factor: 6.065
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.